6453 related articles for article (PubMed ID: 24756797)
21. Activity of trametinib in K601E and L597Q BRAF mutation-positive metastatic melanoma.
Bowyer SE; Rao AD; Lyle M; Sandhu S; Long GV; McArthur GA; Raleigh JM; Hicks RJ; Millward M
Melanoma Res; 2014 Oct; 24(5):504-8. PubMed ID: 24933606
[TBL] [Abstract][Full Text] [Related]
22. Combined blockade of Tim-3 and MEK inhibitor enhances the efficacy against melanoma.
Liu Y; Cai P; Wang N; Zhang Q; Chen F; Shi L; Zhang Y; Wang L; Hu L
Biochem Biophys Res Commun; 2017 Mar; 484(2):378-384. PubMed ID: 28132803
[TBL] [Abstract][Full Text] [Related]
23. Novel mitogen-activated protein kinase kinase inhibitors.
Chapman MS; Miner JN
Expert Opin Investig Drugs; 2011 Feb; 20(2):209-20. PubMed ID: 21235429
[TBL] [Abstract][Full Text] [Related]
24. A phase 2 study of trametinib for patients with pediatric glioma or plexiform neurofibroma with refractory tumor and activation of the MAPK/ERK pathway: TRAM-01.
Perreault S; Larouche V; Tabori U; Hawkin C; Lippé S; Ellezam B; Décarie JC; Théoret Y; Métras MÉ; Sultan S; Cantin É; Routhier MÈ; Caru M; Legault G; Bouffet É; Lafay-Cousin L; Hukin J; Erker C; Jabado N
BMC Cancer; 2019 Dec; 19(1):1250. PubMed ID: 31881853
[TBL] [Abstract][Full Text] [Related]
25. Trametinib for the treatment of melanoma.
Alluri N; Jimeno A
Drugs Today (Barc); 2013 Aug; 49(8):491-8. PubMed ID: 23977666
[TBL] [Abstract][Full Text] [Related]
26. Targeting MEK in a Translational Model of Histiocytic Sarcoma.
Takada M; Hix JML; Corner S; Schall PZ; Kiupel M; Yuzbasiyan-Gurkan V
Mol Cancer Ther; 2018 Nov; 17(11):2439-2450. PubMed ID: 30135215
[TBL] [Abstract][Full Text] [Related]
27. Trametinib, a first-in-class oral MEK inhibitor mass balance study with limited enrollment of two male subjects with advanced cancers.
Ho MY; Morris MJ; Pirhalla JL; Bauman JW; Pendry CB; Orford KW; Morrison RA; Cox DS
Xenobiotica; 2014 Apr; 44(4):352-68. PubMed ID: 23971497
[TBL] [Abstract][Full Text] [Related]
28. Cobimetinib (GDC-0973, XL518).
Andrlová H; Zeiser R; Meiss F
Recent Results Cancer Res; 2018; 211():177-186. PubMed ID: 30069767
[TBL] [Abstract][Full Text] [Related]
29. Combined BRAF and MEK inhibition for the treatment of BRAF-mutated metastatic melanoma.
Queirolo P; Picasso V; Spagnolo F
Cancer Treat Rev; 2015 Jun; 41(6):519-26. PubMed ID: 25944484
[TBL] [Abstract][Full Text] [Related]
30. Enhancer Remodeling during Adaptive Bypass to MEK Inhibition Is Attenuated by Pharmacologic Targeting of the P-TEFb Complex.
Zawistowski JS; Bevill SM; Goulet DR; Stuhlmiller TJ; Beltran AS; Olivares-Quintero JF; Singh D; Sciaky N; Parker JS; Rashid NU; Chen X; Duncan JS; Whittle MC; Angus SP; Velarde SH; Golitz BT; He X; Santos C; Darr DB; Gallagher K; Graves LM; Perou CM; Carey LA; Earp HS; Johnson GL
Cancer Discov; 2017 Mar; 7(3):302-321. PubMed ID: 28108460
[TBL] [Abstract][Full Text] [Related]
31. Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy.
Friday BB; Adjei AA
Clin Cancer Res; 2008 Jan; 14(2):342-6. PubMed ID: 18223206
[TBL] [Abstract][Full Text] [Related]
32. Cobimetinib and trametinib inhibit platelet MEK but do not cause platelet dysfunction.
Unsworth AJ; Bye AP; Kriek N; Sage T; Osborne AA; Donaghy D; Gibbins JM
Platelets; 2019; 30(6):762-772. PubMed ID: 30252580
[TBL] [Abstract][Full Text] [Related]
33. Xanthogranulomatous reaction to trametinib for metastatic malignant melanoma.
Min MS; Yao J; Chee N; Sapadin AN; Shim-Chang H
Cutis; 2018 Oct; 102(4):283-286. PubMed ID: 30489553
[TBL] [Abstract][Full Text] [Related]
34. MEK inhibitors in oncology: a patent review (2015-Present).
Mahapatra DK; Asati V; Bharti SK
Expert Opin Ther Pat; 2017 Aug; 27(8):887-906. PubMed ID: 28594589
[TBL] [Abstract][Full Text] [Related]
35. MEK-ERK signaling is a therapeutic target in metastatic castration resistant prostate cancer.
Nickols NG; Nazarian R; Zhao SG; Tan V; Uzunangelov V; Xia Z; Baertsch R; Neeman E; Gao AC; Thomas GV; Howard L; De Hoedt AM; Stuart J; Goldstein T; Chi K; Gleave ME; Graff JN; Beer TM; Drake JM; Evans CP; Aggarwal R; Foye A; Feng FY; Small EJ; Aronson WJ; Freedland SJ; Witte ON; Huang J; Alumkal JJ; Reiter RE; Rettig MB
Prostate Cancer Prostatic Dis; 2019 Dec; 22(4):531-538. PubMed ID: 30804427
[TBL] [Abstract][Full Text] [Related]
36. Preclinical activity of EGFR and MEK1/2 inhibitors in the treatment of biliary tract carcinoma.
Cavalloni G; Peraldo-Neia C; Varamo C; Chiorino G; Sassi F; Aglietta M; Leone F
Oncotarget; 2016 Aug; 7(32):52354-52363. PubMed ID: 27429047
[TBL] [Abstract][Full Text] [Related]
37. Antitumor activity of the MEK inhibitor trametinib on intestinal polyp formation in Apc(Δ716) mice involves stromal COX-2.
Fujishita T; Kajino-Sakamoto R; Kojima Y; Taketo MM; Aoki M
Cancer Sci; 2015 Jun; 106(6):692-699. PubMed ID: 25855137
[TBL] [Abstract][Full Text] [Related]
38. MEK inhibitors under development for treatment of non-small-cell lung cancer.
Kim C; Giaccone G
Expert Opin Investig Drugs; 2018 Jan; 27(1):17-30. PubMed ID: 29216787
[TBL] [Abstract][Full Text] [Related]
39. A phase I/Ib study of trametinib (GSK1120212) alone and in combination with gemcitabine in Japanese patients with advanced solid tumors.
Kasuga A; Nakagawa K; Nagashima F; Shimizu T; Naruge D; Nishina S; Kitamura H; Kurata T; Takasu A; Fujisaka Y; Okamoto W; Nishimura Y; Mukaiyama A; Matsushita H; Furuse J
Invest New Drugs; 2015 Oct; 33(5):1058-67. PubMed ID: 26259955
[TBL] [Abstract][Full Text] [Related]
40. Targeting RAS/RAF/MEK/ERK signaling in metastatic melanoma.
Wang AX; Qi XY
IUBMB Life; 2013 Sep; 65(9):748-58. PubMed ID: 23893853
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
